| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Catherine J Lucas, Peter Galettis, Jennifer Schneide. The pharmacokinetics and the pharmacodynamics of cannabinoids. British journal of clinical pharmacology. vol 84. issue 11. 2019-11-14. PMID:30001569. |
cannabis medicines contain a wide variety of chemical compounds, including the cannabinoids delta-9-tetrahydrocannabinol (thc), which is psychoactive, and the nonpsychoactive cannabidiol (cbd). |
2019-11-14 |
2023-08-13 |
Not clear |
| Ricardo Jorge Dinis-Oliveir. [The Clinical Toxicology Perspective on the Therapeutic Use of Cannabis and Cannabinoids]. Acta medica portuguesa. vol 32. issue 2. 2019-11-12. PMID:30896388. |
[the clinical toxicology perspective on the therapeutic use of cannabis and cannabinoids]. |
2019-11-12 |
2023-08-13 |
Not clear |
| Ana Juknat, Fuying Gao, Giovanni Coppola, Zvi Vogel, Ewa Kozel. miRNA expression profiles and molecular networks in resting and LPS-activated BV-2 microglia-Effect of cannabinoids. PloS one. vol 14. issue 2. 2019-11-08. PMID:30742662. |
we previously reported that the psychoactive cannabinoid Δ9-tetrahydrocannabinol (thc) and the non-psychoactive cannabidiol (cbd) differ in their anti-inflammatory signaling pathways. |
2019-11-08 |
2023-08-13 |
Not clear |
| M Camiller. Cannabinoids and gastrointestinal motility: Pharmacology, clinical effects, and potential therapeutics in humans. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society. vol 30. issue 9. 2019-11-06. PMID:29745439. |
cannabinoid agents and cannabis are frequently used for relief of diverse gastrointestinal symptoms. |
2019-11-06 |
2023-08-13 |
Not clear |
| Wayne Hall, Daniel Stjepanović, Jonathan Caulkins, Michael Lynskey, Janni Leung, Gabrielle Campbell, Louisa Degenhard. Public health implications of legalising the production and sale of cannabis for medicinal and recreational use. Lancet (London, England). vol 394. issue 10208. 2019-11-06. PMID:31657733. |
second, we summarise evidence regarding the effectiveness of cannabinoids for medicinal use and describe approaches that have been used to regulate the use of medicinal cannabis and how these approaches might have affected medicinal and recreational use and harms (eg, road crashes). |
2019-11-06 |
2023-08-13 |
Not clear |
| Thomas F Gamage, Charlotte E Farquhar, Ryan J McKinnie, Richard C Kevin, Iain S McGregor, Mark L Trudell, Jenny L Wiley, Brian F Thoma. Synthetic Cannabinoid Hydroxypentyl Metabolites Retain Efficacy at Human Cannabinoid Receptors. The Journal of pharmacology and experimental therapeutics. vol 368. issue 3. 2019-10-31. PMID:30552295. |
synthetic cannabinoids (scs) are novel psychoactive substances that are easily acquired, widely abused as a substitute for cannabis, and associated with cardiotoxicity and seizures. |
2019-10-31 |
2023-08-13 |
human |
| b' Roberta Pacifici, Simona Pichini, Manuela Pellegrini, Roberta Tittarelli, Flaminia Pantano, Giulio Mannocchi, Maria Concetta Rotolo, Francesco Paolo Busard\\xc3\\xb. Determination of cannabinoids in oral fluid and urine of "light cannabis" consumers: a pilot study. Clinical chemistry and laboratory medicine. vol 57. issue 2. 2019-10-28. PMID:30332386.' |
determination of cannabinoids in oral fluid and urine of "light cannabis" consumers: a pilot study. |
2019-10-28 |
2023-08-13 |
Not clear |
| b' Roberta Pacifici, Simona Pichini, Manuela Pellegrini, Roberta Tittarelli, Flaminia Pantano, Giulio Mannocchi, Maria Concetta Rotolo, Francesco Paolo Busard\\xc3\\xb. Determination of cannabinoids in oral fluid and urine of "light cannabis" consumers: a pilot study. Clinical chemistry and laboratory medicine. vol 57. issue 2. 2019-10-28. PMID:30332386.' |
we here report a pilot study on the determination of cannabinoids in the oral fluid and urine of six individuals after smoking 1 g of "light cannabis". |
2019-10-28 |
2023-08-13 |
Not clear |
| Tom P Freeman, Celia Morgan, Chandni Hindoch. Strengthening the evidence for medicinal cannabis and cannabinoids. BMJ (Clinical research ed.). vol 367. 2019-10-24. PMID:31636061. |
strengthening the evidence for medicinal cannabis and cannabinoids. |
2019-10-24 |
2023-08-13 |
Not clear |
| Eleonore Deceuninck, Denis Jacque. Cannabinoid hyperemesis syndrome: a review of the literature. Psychiatria Danubina. vol 31. issue Suppl 3. 2019-10-23. PMID:31488758. |
cannabinoid hyperemesis syndrome (chs) is characterized by cyclic vomiting and compulsive need to take hot showers in the context of chronic cannabis use. |
2019-10-23 |
2023-08-13 |
Not clear |
| Carmen Del Rio, Irene Cantarero, Belén Palomares, María Gómez-Cañas, Javier Fernández-Ruiz, Carolina Pavicic, Adela García-Martín, Maria Luz Bellido, Rafaela Ortega-Castro, Carlos Pérez-Sánchez, Chary López-Pedrera, Giovanni Appendino, Marco A Calzado, Eduardo Muño. VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPARγ- and CB British journal of pharmacology. vol 175. issue 19. 2019-10-17. PMID:30033591. |
vce-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through pparγ- and cb the endocannabinoid system and pparγ are important targets for the development of novel compounds against fibrotic diseases such as systemic sclerosis (ssc), also called scleroderma. |
2019-10-17 |
2023-08-13 |
Not clear |
| C Hindocha, T P Freeman, M Grabski, H Crudgington, A C Davies, J B Stroud, R K Das, W Lawn, C J A Morgan, H V Curra. The effects of cannabidiol on impulsivity and memory during abstinence in cigarette dependent smokers. Scientific reports. vol 8. issue 1. 2019-10-15. PMID:29765102. |
cannabidiol (cbd), the non-intoxicating cannabinoid found in cannabis, has shown pro-cognitive effects and preliminary evidence has indicated it can reduce the number of cigarettes smoked in dependent smokers. |
2019-10-15 |
2023-08-13 |
human |
| Stefania Petrosino, Roberta Verde, Massimo Vaia, Marco Allarà, Teresa Iuvone, Vincenzo Di Marz. Anti-inflammatory Properties of Cannabidiol, a Nonpsychotropic Cannabinoid, in Experimental Allergic Contact Dermatitis. The Journal of pharmacology and experimental therapeutics. vol 365. issue 3. 2019-10-14. PMID:29632236. |
anti-inflammatory properties of cannabidiol, a nonpsychotropic cannabinoid, in experimental allergic contact dermatitis. |
2019-10-14 |
2023-08-13 |
Not clear |
| Maira Aguiar Werneck, Guilherme Trevizan Kortas, Arthur Guerra de Andrade, João Mauricio Castaldelli-Mai. A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms. CNS drugs. vol 32. issue 12. 2019-10-14. PMID:30361897. |
a systematic review of the efficacy of cannabinoid agonist replacement therapy for cannabis withdrawal symptoms. |
2019-10-14 |
2023-08-13 |
Not clear |
| Patrícia Schonhofen, Ivi Juliana Bristot, José Alexandre Crippa, Jaime Eduardo Cecílio Hallak, Antônio Waldo Zuardi, Richard B Parsons, Fábio Klam. Cannabinoid-Based Therapies and Brain Development: Potential Harmful Effect of Early Modulation of the Endocannabinoid System. CNS drugs. vol 32. issue 8. 2019-10-10. PMID:30109642. |
cannabidiol (cbd) is one of the most studied exogenous cannabinoids, and cbd-enriched cannabis extracts have been widely (and successfully) used as adjuvants to treat children with refractory epilepsy, and there is even a food and drug administration (fda)-approved drug with purified cbd derived from cannabis. |
2019-10-10 |
2023-08-13 |
Not clear |
| A Suraev, N Lintzeris, J Stuart, R C Kevin, R Blackburn, E Richards, J C Arnold, C Ireland, L Todd, D J Allsop, I S McGrego. Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community. Scientific reports. vol 8. issue 1. 2019-10-09. PMID:29977078. |
for those using cannabis, extracts were analysed for cannabinoid content, with specific comparison of samples rated by families as "effective" versus those rated "ineffective". |
2019-10-09 |
2023-08-13 |
Not clear |
| A Suraev, N Lintzeris, J Stuart, R C Kevin, R Blackburn, E Richards, J C Arnold, C Ireland, L Todd, D J Allsop, I S McGrego. Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community. Scientific reports. vol 8. issue 1. 2019-10-09. PMID:29977078. |
there was high variability in the cannabinoid content and profile of cannabis extracts rated as "effective", with no clear differences between extracts perceived as "effective" and "ineffective". |
2019-10-09 |
2023-08-13 |
Not clear |
| Rudolf Likar, Markus Koestenberger, Martin Stultschnig, Gerhard Nahle. Concomitant Treatment of Malignant Brain Tumours With CBD - A Case Series and Review of the Literature. Anticancer research. vol 39. issue 10. 2019-10-07. PMID:31570484. |
in recent years, an increasing number of data from in vitro and in vivo research with cannabinoids, particularly with the non-intoxicating cannabidiol (cbd), point to their potential role as tumour-inhibiting agents. |
2019-10-07 |
2023-08-13 |
Not clear |
| Emily Stockings, Dino Zagic, Gabrielle Campbell, Megan Weier, Wayne D Hall, Suzanne Nielsen, Geoffrey K Herkes, Michael Farrell, Louisa Degenhard. Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. Journal of neurology, neurosurgery, and psychiatry. vol 89. issue 7. 2019-10-04. PMID:29511052. |
evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. |
2019-10-04 |
2023-08-13 |
human |
| Tory R Spindle, Edward J Cone, Nicolas J Schlienz, John M Mitchell, George E Bigelow, Ronald Flegel, Eugene Hayes, Ryan Vandre. Acute Pharmacokinetic Profile of Smoked and Vaporized Cannabis in Human Blood and Oral Fluid. Journal of analytical toxicology. vol 43. issue 4. 2019-10-04. PMID:30615181. |
this study compared the concentrations of cannabinoids in whole blood and oral fluid after administration of smoked and vaporized cannabis in healthy adults who were infrequent users of cannabis. |
2019-10-04 |
2023-08-13 |
human |